Skip to main content

Table 6 Laboratory data of patients classified by serological status of HEV during 2015–2018

From: Prevalence and clinical correlation of hepatitis E virus antibody in the patients’ serum samples from a tertiary care hospital in Thailand during 2015–2018

Laboratory data Age (years) AST (U/L) ALT (U/L) ALP (U/L) Total bilirubin (mg/dL)
All cases (n = 796) 49 (0.03–94) 204 (10–7778) 217 (6–7000) 163 (32–3346) 2.9 (0.2–56.7)
Group I 48 (0.08–94) 195 (10–7778) 236 (7–6247) 163 (32–3346) 2.4 (0.2–49.4)
 HEV IgG− HEV IgM− (n = 456)
Group II 50 (0.08–93) 185 (14–7000) 167 (6–7000) 170 (41–1422) 4.3 (0.2–56.7)
 HEV IgG+ HEV IgM− (n = 233)
Group III 48.5 (4–59) 135.5 (30–915) 330 (19–1974) 212.5 (173–348) 1.6 (0.2–9.9)
 HEV IgG− HEV IgM+ (n = 6)
Group IV 50 (0.03–91) 262 (16–3408) 343 (7–3383) 163 (51–1348) 3.9 (0.3–36.7)
 HEV IgG+ HEV IgM+ (n = 101)
P-value 0.125 0.224 0.039* 0.573 0.017*
  1. A total number of 796 serum samples, which were sent for detection of both anti-HEV IgG and IgM antibodies, were analyzed according to the HEV serological status. General patient information and laboratory data, including age, AST, ALT, ALP, and total bilirubin, were demonstrated in median and range. Distributions across four HEV serological statuses (Group I: HEV IgG−/IgM−, Group II: HEV IgG+/IgM−, Group III: HEV IgG−/IgM+, and Group IV: HEV IgG+/IgM+) were compared using the Kruskal–Wallis test. A P-value less than 0.05 is considered statistical significance